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Objective: To investigate the pharmacodynamic disposition of two recently developed p-lactam antibiotics, meropenem 
and cefpirome, in the Yucatan micropig model, and to compare the bactericidal activity of these drugs against bacteria 
in this in vitro/ex vivo micropig model after administration by both intermittent injection and continuous infusion. 
Methods: Cefpirome ( 1  g) was given to the micropig over a 12-h period by direct intravenous injection and 6-h 
continuous infusion (500 mg). Meropenem (250 mg) was administered either by 30-min intravenous and 8-h continuous 
infusion. The two drugs were assayed by HPLC. The pharmacodynamics of these drugs were evaluated by means of (1) 
serum killing curve against Klebsiella pneurnoniae producing extended-spectrum 0-lactamase, stably derepressed 
Enrerobacter cloacae and methicillin-susceptible penicillinase-producing Staphylococcus aureus, and (2) calculations of 
index of surviving bacteria (ISB). 
Results: The bactericidal activity of meropenem against K. pneurnoniae and €. cloacae in this in vitro/ex vivo model 
was excellent, with a 4 log decrease at peak concentrations. Meropenem produced a mixed concentration- and time- 
dependent, killing effect against €. cloacae and K. pneumoniae. The ISB value ranged from 25% to 30% for €. cloacae. 
With concentrations above MIC for S. aureus (1 mg/L), cefpirome has a time-dependent bactericidal activity, as shown 
by the ISB ranging from 20% to 80% after 4 h and between 20% and 40% after an 8-h drug exposure. For both antibiotics, 
the higher concentrations obtained just after intermittent injection had a rapid and strong killing effect against the strains 
tested, but the trough levels had no bactericidal activity. The continuous infusions produce consistent concentrations of 
antibiotic that can be maintained above the MIC, and the bactericidal activity of which ranges from 2 to 4 loglo decrease 
of inoculum. 
Conclusions: In the present study the micropig has been shown to be an adequate model for the pharmacodynamic 
investigation of cefpirome and meropenem. In general, continuous infusion appears to optimize the pharmacodynamic 
profile of the two tested p-lactam antibiotics. However, against Gram-negative bacilli, the administration of a loading 
dose prior to continuous infusion of 0-lactams would eliminate the only potential pharmacokinetic disadvantage of 
continuous infusion and ensure the rapid onset of antimicrobial activity. 
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INTRODUCTION 
Many antimicrobial p-lactams have been recently 
developed for clinical use, including a new carbapenem 
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(meropenem) and an extended-spectrum cephalo- 
sporin (cefpirome). Meropenem is highly resistant to 
the hydrolytic activity of plasmid-mediated extended- 
spectrum 0-lactamases (ESBLs) arid highly stable to 
class C P-lactamases (chromosomal cephalosporinases) 
[1,2]. It differs from the currently available member of 
this class, imipenem-cilastatin, by having a 1 P-methyl 
substitution which improves stability to renal 
dehydropeptidase-I [31. Cefpirome is a semisynthetic 
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cephalosporin with a broad spectrum of antimicrobial 
activity. In comparison with third-generation cephalo- 
sporins, cefpirome demonstrates increased in-vitro 
activity against Staphylococcus, Enterococcus and Entero- 
bacter spp. [4]. Cefpirome has been reported to have 
good P-lactamase stability combined with rapid 
penetration of the outer membrane [5]. The optimal 
dosing regimen for an antimicrobial agent is dependent 
on both the pharmacokinetics and pharmacodynamics 
of the drug. Continuous ir&sion of 0-lactams has been 
advocated for years as an alternative method of 
administration on the basis of their pharmacodynamics 
[6-81. The time during which the drug concentrations 
exceed the MIC is thought to be the major 
determinant of ef5cacy with p-lactam antibiotics. Most 
0-lactam antibiotics exhibit these pharmacodynamic 
characteristics particularly with Gram-negative bacilli 
[6,9]. The aim of this study was (1) to validate the 
Yucatan micropig as a reliable model for pharmaco- 
kinetic investigation of meropenem and cefpirome, and 
(2) to compare the serum killing curves in an ex- 
vivo/in-vitro micropig model of two cefpirome and 
rneropenem regimens administered by continuous 
infusion and by intermittent injection. 
ANIMALS AND METHODS 
Animals 
Three adult female Yucatan micropigs were included in 
each group. They ranged from 26 to 39 kg. The pigs 
were anesthetized and a polyurethane catheter 
(60 cmX2 mm) was surgically placed in the external 
jugular vein for blood collection. The details of catheter 
maintenance are described in our previous reports [lo]. 
Drugs assay 
Meropenem and cefpirome concentrations in serum 
were determined by an HPLC technique as previously 
described [11,12]. Briefly, serum (500 pL) was depro- 
teinized with 500 pL of acetonitrile in a 5-mL screw- 
capped glass tube on a vortex mixer. The tube was 
gently shaken by rotation (20 rev/min) and then 
centrifuged for 10 min at 10OOg. The supernatant was 
transferred to another screw-capped glass tube and 
3.2 mL of methylene chloride was added. After 
rotation (20 rev/min) for 10 min and centrifugation at 
lOOOg for 10 min, 5- and 20-pL aliquots, respectively, 
of the upper aqueous layer were injected into the 
apparatus for meropenem and cef$irome assay. 
Study design 
The injection of the antibiotics into micropigs was 
performed through a winged infusion set introduced 
into an ear vein. On the basis of the mean weight of 
the animals (35 kg, i.e. roughly half the weight of a 
human), the administered doses were half of those 
commonly used in clinical practice. Cefpirome was 
given by direct intravenous injection (1 g) and 6-h 
continuous infusion (500 mg). Blood samples were 
drawn via the jugular catheter before administration 
and at 1 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 
6 h, 8 h and 12 h after bolus injection. For continuous 
infusion, blood samples were obtained before infusion 
and at 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 5 hand 
6 h after the beginning of administration. Meropenem 
(250mg) was given by 30-min short and 8-h 
continuous infusion. For 30-min short infusion, the 
blood samples were drawn before administration and at 
15min,30min, l h ,  l S h , 2 h , 3 h , 4 h , 6 h a n d 8 h .  
With administration by continuous infusion, the 
scheme for blood sampling was slightly different: before 
administration and at 15 min, 30 min, 1 h, 1.5 h, 2 h 
and each hour afterwards until 8 h. For continuous 
infusion, cefpirome (500 mg) and meropenem (250 mg) 
were diluted in sodium chloride (0.9%); packaged 
in a 50-mL syringe, and infused constantly with an 
infusion pump over 6 h for cefpirome and over 8 h 
for meropenem. 
Pharmacokinetic analysis 
Standard kinetic parameters were determined [13]. The 
peak serum levels (C,,), residual serum concentrations 
( Cmn) and steady-state concentrations ( Css) were 
obtained by direct observation of the individual kinetic 
profiles. The area under the serum concentrations-time 
curves (AUC) was calculated using the trapezoidal rule 
and included all experimental data points. The terminal 
half-life was estimated by linear regression analysis 
using computerized Software (Siphar, Simed, France). 
Total body clearance was calculated as being the given 
dose divided by the AUC and was normalized to body 
weight. In the case of continuous infusion, the clear- 
ance was calculated as being the drug infusion rate 
(mg/min) divided by the steady-state concentration 
and was normalized to body weight. Results are given 
as mean (&standard deviation). 
Test bacteria 
The pharmacodynamics of both drugs, whichever the 
mode of administration, as well as the kinetics of 
bactericidal activity of animal serum were investigated 
using fresh clinical isolates of methicillin-susceptible 
penicillinase-producing Staphylococcus aureus, ESBL- 
producing Klebsiella pneumoniae and stably derepressed 
Enterobacter cloacae producing a high-level cephalo- 
sporinase. 
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MIC and MBC determination 
Minimum inhibitory concentrations (MICs) were 
determined by serial macrodilution in MueUer-Hinton 
(MH) broth, with dilutions ranging from 256 mg/L to 
0.125 mg/L. The inoculum was prepared from an 
overnight culture suitably diluted to obtain 106-107 
CFU/mL. Inoculated plates (MH agar) for minimum 
bactericidal concentration (MBCs) determination were 
read after overnight incubation. An MBC was defined 
as the lowest concentration leaving only 0.01% sur- 
viving bacteria. 
Pharmacodynamic analysis 
Each serum sample was diluted from 112 to 1/256 in 
MH broth plus 5% bovine serum albumin and was 
inoculated with a suspension of the test strains. The 
starting inoculum consisted of an overnight culture 
appropriately diluted to give 106-107 CFU/mL. The 
bacteria were used in the stationary phase. At fixed 
intervals ho, h 2 ,  124 and h6 (except for S. aureus, for 
which counts were performed over 8 h) a sample of the 
culture was taken and serially diluted (10-fold) in saline. 
The ‘carryover’ phenomenon was thus avoided by 
using this dilution technique. Each dilution was then 
seeded on an MH medium using a spiral system. After 
overnight incubation a t  37OC, the colonies, corres- 
ponding to the surviving organisms, were automatically 
counted using a ‘Scan 500’ camera system (Inter- 
sciences, France). 
Expression of results 
For each dilution of each micropig serum sample, the 
surviving bacteria, expressed on a loglo scale, were 
plotted against duration of incubation (from 0 to 6 or 
8 h). Thus, for each dilution, a curve of number of 
CFU per mL versus time was obtained, the area under 
which could be calculated using a simple trapezoidal 
rule. The calculated ratio of this experimental AUC to 
the starting inoculum AUC (equivalent to starting 
inoculum multiplied by the duration of incubation, 6 
or 8 h) was considered as the index of surviving bacteria 
(ISB), expressed as a percentage of starting inoculum. 
Thus, the lower the ISB, the higher the bactericidal 
activity of the correspondmg dilution. A lo2 CFU/mL 
value was considered as the limit of detection of the 
counting method. 
For each dilution o€ each serum, an ISB was 
calculated. As an antibiotic concentration corres- 
ponded to each dilution (i.e. the concentration 
measured in the sampled serum divided by the factor 
of dilution), we could plot the ISB value against the 
antibiotic concentrations to demonstrate the mode of 
killing of both antibiotics. 
RESULTS 
Susceptibility results as determined by an end-point 
method 
The MICs of meropenem were 0.25 and 0.5 mg/L for 
ESBL-producing K. pneurnoniae and stably derepressed 
E. cloacae, respectively. The MICs and MBCs were 
similar for those strains. Both MICs and MBCs of 
cefpirome for methicillin-susceptible, penicillinase- 
producing S. a w e u s  were 1 mg/L, and they were 64 and 
128 mg/L, respectively, for E. cloacae. 
Pharmacokinetic and pharmacodynamic parameters 
The pertinent pharinacokinetic parameters of 
meropenem and cefpirome for both dosing regimens 
are given in Tables 1 and 2, together with a comparison 
with human values. 
Meropenem 
At meropenem concentrations above 0.1 mg/L (Figure 
l), the ISB values for E. cloacae were stable at  about 
25-30% after a 4-h contact period between bacteria 
and antibiotic. Between 0.01 and 0.1 mg/L, there is 
clearly concentration-dependent killing activity. The 
bactericidal activity of meropenem related to the 
concentration achieved a t  the end of short antibiotic 
Table 1 Pharmacokinetlc characteristics of meropeneni and comwrison with human values 
Value (mean%SU) 
Micropig Human 
Characteristic (units) Short infusion Continuous infusion Short infusion 
0.7810.34 
29.8k1.27 
<o. 1 
27.422 4 
4.6? 1 .OO 
- 
I1 4620.01 
2.38+0.50 
17.5i4.10 
7.320.77 
O.HO-eO.02 
24.8C1.4O 
10 .2  
27.222.20 
3.68 
- 
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Table 2 Pharmacolunetic characteristics of cefpirome in micropig, and comparison with human values 
Value (mean5SD) 
Characteristic 
(units) 
Micropig Human 
Intermittent Continuous Intermittent 
injection i n h i o n  injection 
Tiiz (h) 1.44k0.25 1.35k0.42 1.820.20 
Cm, (pg/mL) 544.6k157.3 - 200 
cm, (WnL) 1.1621.0 1 
css (pg/mL) - 20.954.10 - 
- 
AUC (pg h/mL) 308.9245.1 108.7?16.7 312.6 
CiP (mL/min per kg) 1.59k0.10 1.8850.37 1.8050.20 
I 
rneropenem concentration (mg/L) 
Figure 1 Relationship between ISB (see text) and meropenem concentrations for E. cloacae after 4 h of contact. 
infusion (CmJ was rapid and strong, with about a 
4 loglo decrease of starting inoculum occurring after a 
6-h period of drug exposure (Table 3). When 
considering the bactericidal activity of the 1/2-diluted 
serum as a function of times of sampling (Figure 2), 4 h 
after short infusion of meropenem the micropig serum 
concentrations fell below 0.1 mg/L and bacterial 
regrowth occurred. Continuous infusion appeared to 
provide adequate concentrations in serum during the 
interval of administration, as bactericidal activity 
against E. cloacae was maintained throughout this 
interval (Figure 2) .  The kding activity of meropenem 
against K. pneumoniae was excellent. It appeared that it 
was similar to that shown for E. cloacae. The evaluation 
of the serum bactericidal activity expressed by the 
starting inoculum decrease showed that with high 
concentrations of meropenem (end of short infusion), 
the strain was rapidly and thoroughly killed (more than 
4 loglo decrease after a 6-h exposure) (Table 3). As 
previously seen with E. cloacae, bacteria began to 
regrow 6 h after intermittent meropenem injection. 
Conversely, meropenem conserved its antimicrobial 
activity throughout the continuous infusion (Figure 3). 
Cefpirome 
The evaluation of the bactericidal activity of serum 
against S. aureus showed that the pharmacodynamic 
behavior of cekirome is clearly concentration 
independent. Above the MIC for S.  aureus (1 mg/L), 
the ISBs ranged from 20% to 80% after 4 h (Figure 4A) 
and slowly decreased to 20-40% after 8 h of exposure 
to serum (Figure 4B). The C,, achieved after 
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Table 3 Serum (diluted to 1/2) bactericidal activity of meropenem and cefpirome. Results expressed in increase (+) or 
decrease (-) of loglo CFU/mL compared to starting inoculum after 6 h (K.  pneumoniae and E. chacae) and 8 h (S. aureur) 
drug exposure 
C,,, ( s i )  C, ( s i )  Cs, (c.i.) 
Concentration Coticetitration Concentration 
Antibiotic Strain ( r g / W  A log A log (pg/mL) A log 
Meroprnem K. prietimoniae 29.8 -4.2 < O . l  +1.4 2.04 -3.9 
Cefpirome S ,  aweus 541.6 -2.6 1.16 fO.5 18.4 -1.7 
E.  cloacae 29.8 -4.2 < O . l  i 0 . 5  2.04 -3.6 
E. cloacae 544.6 -3.4 1.16 +1.2 18.4 -2.0 
- 
- 
- 
- 
- 
- 
- - 
2 0 - -  - " " " " - 0 
I I I I I 
s.i., short infusion; c.i., continuous infusion 
180 2oo F 
--t short infusion - continuous infusion 
Figure 2 Bactericidal activity against E.  cloacae (6-h exposure) of micropig serum dduted to 1/2 versus time profiles 
following administration of meropenem by intravenous short infusion and continuous infusion. 
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Figure 3 Bactericidal activity against K. pneutnoniae (6 h exposure) of micropig serum diluted to 2 / 2  versus time profiles 
following administration of meropenem by intravenous short infbsion and continuous infusion. 
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Figure 4 Relationship between ISB and cefI)irome concentrations for S.  aureus after 4 h (A) and 8 h (B) of contact. 
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Figure 5 Relationship between ISB and cefpirome concentrations for E.  cloacae after 6 h of contact. 
continuous infusion produced a nearly 2 log10 decrease 
of starting inoculum after 8 h of drug exposure. 
Following bolus injection, bacteria began to regrow 
when serum reached trough concentration (i.e. C,,,) 
(Table 3). In contrast, increasing cefpirome concen- 
tration (C,,,,,, bolus injection) did not enhance the 
killing rate observed at C,, of continuous infusion 
(Table 3). 
Against E.  cloacae, by the mean of time-killing 
curves, bactericidal activity of cefpirome was observed 
in the early phase with low concentrations, despite the 
high MIC (64 mg/L). No correlation was observed 
between cefpirome concentrations and ISB values 
(Figure 5). The bolus dosing schedule produced a high 
peak antibiotic serum concentration for cefpirome 
which permitted rapid and pronounced bactericidal 
activity against E.  cloacae (1.e. C,,,) (Table 3). 
Therefore, more than a 3 loglo decrease occurred (6-h 
exposure). As previously seen, in the early phase of 
bactericidal kdling, cefpirome maintained antimicrobial 
activity throughout the continuous infusion. Conversely, 
regrowth occurred when the concentration fell to 
trough level after bolus injection (i.e. C,,,) (Table 3 ) .  
DISCUSSION 
The increasing number of immunocompromised 
patients and the rising incidence of bacterial infections 
have added impetus to the development of dosage 
regimens that will achieve the most benefit with the 
least amount of drug [14]. With regard to p-lactam 
antibiotics, there still is controversy about dosage. In 
clinical practice the p-lactams are administered 
intermittently However, the length of time for which 
MICs can be exceeded is generally considered to 
correlate well with therapeutic efficacy and this favors 
frequent administration or continuous infusion [6,7). 
The several methods used to evaluate the new 
antibiotics, particularly in permitting a comparison of 
their relative efficacy against a given microorganism, 
reflect a very limited perspective on the in-vivo 
situation. The MIC is not a reliable reflection of 
antibiotic activity, as it shows a fixed 24-h endpoint and 
as many antibiotics are not stable for a whole 24-h 
period of contact in certain conditions. For example, 
we have recently demonstrated that cefepime and 
meropenem are unstable in serum at room temperature 
[11,15]. Conversely, the MIC does not provide 
information on the total effect of a certain dose of the 
antibiotic in a larger range of concentrations, as is 
characteristically encountered in the patient. 
Micropigs have been recognized as being an 
appropriate non-rodent model for pharmacologic 
studies owing to physiologic similarities to humans 
[16]. Despite these potential advantages, micropigs are 
seldom used in pharmacokinetic investigations and 
hence few kinetic data are available. The pharmaco- 
kinetics of meropenem and cefpirome given by short 
infusion and bolus injection, respectively, in the 
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micropig were close to those in humans receiving the 
same dosage. So, on this basis, the micropig seems to 
constitute the most reliable model in which to study 
the pharmacodynamics of these two p-lactams [12]. 
The ex vivo/in vitro time-kill curves demonstrate 
that meropenem produces rapid bactericidal activity 
against E. cloacae and K. pneumoniae at the relatively 
high concentrations (about 30 mg/L) that may be 
reached after short infusion of half the usual doses 
(given that serum was diluted 1/2). However, 
meropenem is simdar to other p-lactams, in that, above 
a threshold level, higher concentrations of drug will not 
kill the organisms faster or more extensively. We 
conclude that meropenem has so-called 'mixed' 
pharmacodynamic behavior. The bactericidal activity 
of any p-lactam antibiotic is usually said to be 
dependent upon time of contact with the bacteria 
rather than on the occurrence of high peaks of 
antibiotic concentration. In fact, we have already 
observed that the pharmacodynamic behavior of p- 
lactams depends on both the bacteria and the antibiotic. 
Furthermore, in the same bacteria-antibiotic pair, this 
relationship is complex and evolves with the resistance 
level of bacteria. We have already shown in an in 
vitro/ex vivo human model that against S.  pneumoniae, 
amoxicillin shows mixed pharmacodynamic behavior 
which is considered as being time and concentration 
dependent [17]. In fact, it depends on the level of 
susceptibility of the strain and must be interpreted by 
taking into account the concentrations achieved at the 
infected site. While the results obtained in our study 
favor continuous infusion of meropenem, the rapid 
killing obtained by somewhat higher levels favors a 
loading dose that could optimize the bactericidal effect. 
In an in vitro infection model, Cappelletty showed that 
ceftazidime monotherapy administered as a continuous 
infusion at 20 and 10 pg/mL with a loading dose is as 
effective as administration of intermittent bolus [18]. 
Avoidance of unnecessarily high values during all the 
intervals would result in lower daily doses, thus 
reducing costs while retaining efficacy by avoiding the 
therapeutic gap. The absence of a postantibiotic effect 
(PAE) both in vitro and in vivo with meropenem 
has already been demonstrated. In the neutropenic 
mouse thigh infected with Escherirhia coli, S.  aureus or 
Pseudomonas aeruginosa, the PAE of meropenem was 
negligible (under 0.3 h). In an in vitro model, this effect 
was estimated at 0.23 h after 1-h period of contact 
between meropenem and one strain of K. pneumoniae 
[19]. Hessen et al studied the PAE in the rat model of 
pseudomonas endocarditis, and showed an absence of 
t h s  effect in vivo. The bacterial counts increased as 
soon as levels of imipenem in the vegetations fell below 
the MIC [20]. Furthermore, the absence of this effect 
has been reported again with imipenem tested against 
Enterobacteriaceae in an in vitro model [21]. Finally, 
intermittent administration seems to be responsible 
for resistance to meropenem, particularly by d2-porin 
deficiency [22]. In conventional treatment regimens, 
meropenem is given intermittently [23,24]. Because of 
its rapid systemic body clearance, this may lead to 
concentrations in plasma below the effective threshold 
during part of the dosing interval and thus may impair 
efficacy. During continuous infusion, a level above this 
threshold may easily be maintained against tested 
bacteria and should prevent emergence of resistance. A 
loading dose of meropenem followed by a continuous 
infusion would be more effective than intermittent 
injection against Gram-negative bacilli. 
The Werence in ce@irome Cmax (Table 2) between 
micropig and human (544.6 versus 200) is likely to be 
due to a slight difference in time sampling together 
with a very short distribution half-life. Only a few 
minutes delay may divide concentrations by two in 
this period. According to our data (Figure 4A,B), 
ce@irome shows time-dependent bactericidal activity 
against S. aureus. According to the coefficients of 
correlation (Figures 4A,B) which are rather low, it 
could be thought that cefpirome exhibits a time- 
dependent bactericidal activity against S. aureus. There 
is no clear relationship between concentrations and ISB 
(Figure 4A), but the overall values of ISB are lower after 
8 h of exposure than after 4 h (Figure 4B), indicating 
at least a partial time-dependent mode of killing. 
Nevertheless, it should be noted on Figure 4B that 
below 1 mg/L, ISB values of more than 50% are 
frequently reached, which is never the case with 
concentrations above 1 mg/L. Thus, the mode of 
killing of cefpirome may also be dependent on the 
concentrations. Intermittent administration results in 
high peak concentrations in serum which do not lull 
S. aureus faster or more extensively than the lower 
concentrations obtained at steady state and which are 
about 20 times higher than the MIC. Trough 
concentrations may fall below the MIC for S. aureu~ at 
the end of the dosing interval (for one micropig &s 
value was 0.5 mg/L) and regrowth could occur. Against 
S. aureus, continuous infusion thus appears to be the 
optimal administration technique to avoid the absence 
ofbactericidal activity observed at the C, that follows 
intermittent injection. As shown for S. aureus, the 
pronounced bactericidal activity of cefpirome against 
E. cloacae (+3.4 loglo decrease at  Cmx) seems to be 
concentration independent (Figure 5), and somewhat 
variable, probably in relation to the cephalosporinase 
production level. Once again, no bactericidal activity is 
observed at Cmn. The 2 loglo decrease of inoculum 
resulting from the C,, (18.4 mg/L) looks rather good 
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compared with the MIC (64mg/L), but would 
probably be insuficient for treating infections due to 
strains with such high MICs. 
Up to now, little information has been available 
concerning in-vitro models, animal models and clinical 
studies comparing the efficacy of continuous infusion 
of p-lactam antibiotics with that following intermittent 
injection [6-91. In the present study, we used the 
Yucatan micropig model, which has been validated in 
pharmacokinetic terms for cefpirorne and rneropenem 
and is thus a pertinent model for the in vitro/ex vivo 
pharrnacodynamic investigations of these p-lactams 
with several multiresistant strains. We conclude that 
continuous infusion seems to be more in accord with 
the pharmacodynamics of ce@irome and rneropenem. 
Against Gram-negative bacilh, the administration of a 
loading dose prior to continuous infusion would 
eliminate the only potential pharmacokinetic dis- 
advantage of continuous infusion and ensure the rapid 
onset of antimicrobial activity. Experimental infection 
wlll be the next step and work is currently in progress. 
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